牛牛AI助理已提取核心訊息
SciSparc Ltd., a company listed in the United States, has received notification from the Division of Corporation Finance Office of Life Sciences, part of the United States Securities and Exchange Commission (SEC), that the review of its Form 20-F for the year ended December 31, 2022, has been completed. The communication, addressed to Oz Adler, the CEO and CFO of SciSparc, dated January 18, 2024, also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review outcome.
SciSparc Ltd., a company listed in the United States, has received notification from the Division of Corporation Finance Office of Life Sciences, part of the United States Securities and Exchange Commission (SEC), that the review of its Form 20-F for the year ended December 31, 2022, has been completed. The communication, addressed to Oz Adler, the CEO and CFO of SciSparc, dated January 18, 2024, also reminds the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review outcome.
在美國上市的公司ScisPARC Ltd. 已收到美國證券交易委員會（SEC）下屬的生命科學公司財務處的通知，對截至2022年12月31日止年度的20-F表格的審查已經完成。這封日期爲2024年1月18日致ScisPARC首席執行官兼首席財務官奧茲·阿德勒的信函還提醒該公司及其管理層，無論美國證券交易委員會的審查結果如何，他們都對披露的準確性和充分性負責。
在美國上市的公司ScisPARC Ltd. 已收到美國證券交易委員會（SEC）下屬的生命科學公司財務處的通知，對截至2022年12月31日止年度的20-F表格的審查已經完成。這封日期爲2024年1月18日致ScisPARC首席執行官兼首席財務官奧茲·阿德勒的信函還提醒該公司及其管理層，無論美國證券交易委員會的審查結果如何，他們都對披露的準確性和充分性負責。
有用
沒用